A participant - and investigator-blinded, randomized, placebo-controlled, multicenter, platform study to investigate efficacy, safety, and tolerability of various single treatments in patients with idiopathic pulmonary fibrosis

Idiopathic pulmonary fibrosis

Change from baseline to end of treatment epoch (26 weeks of treatment) in Forced Vital Capacity (FVC) expressed in percent predicted

Change from baseline to end of treatment epoch (26 weeks of treatment) in Forced Vital Capacity (FVC) expressed in mL, • Time to progression as defined by a composite endpoint including any of the following events: • Absolute reduction from baseline of ≥10% predicted in FVC • Nonelective hospitalization for respiratory events • Lung Transplant • Death, Number of participants with absolute decline of ≥10% predicted in FVC, Change from baseline to the end of treatment epoch (26 weeks of treatment) in DLCO absolute and percent predicted, Change from baseline to the end of treatment epoch (26 weeks of treatment) in 6-minute walk distance, Change from baseline to the end of treatment epoch (26 weeks of treatment) in scores from the L-IPF (Impacts and Symptoms Modules), K-BILD, Leicester cough, and R-Scale for PF questionnaires, Adverse Events, physical examinations, labs, ECGs, vital signs

No related papers found yet.

Czechia, Germany, Netherlands, Poland